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The aim of this research was to determine whether novel pyridinium oximes
synthesized to increase lipophilicity and the likelihood of crossing the blood-brain barrier
could effectively reactivate phosphorylated AChE in vitro. A synthesized sarin analog,
phthalimidyl isopropyl methylphosphonate (PIMP), was used to test the reactivation
potential of the oximes. The reactivation activities of the oximes on PIMP exposed
AChE and structure activity relationships were examined. Differences in reactivation
potential in comparison to the widely used 2-PAM were also examined. All novel oximes
tested demonstrated some ability to reactivate inhibited AChE. Reactivations varied
among the oximes (24%-78%), and were not effective as 2-PAM or TMB-4, 91-97%,
respectively. The lipophilicity for all oximes was greater than 2-PAM or TMB-4 by 3 to
374 fold. A few of the novel oximes showed combined higher lipophilicity and
reactivation potential approaching that of 2-PAM, and therefore suggest some potential
efficacy as brain-penetrating oxime reactivators.
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CHAPTER I
INTRODUCTION
Organophosphates (OPs) were first synthesized in the early 1800’s when
Lassaigne reacted ethanol with phosphoric acid to obtain triethyl phosphate. A hundred
years later in 1936, Gerhard Schrader of Germany discovered nerve agents when trying to
develop new types of insecticides. Schrader discovered the nerve agent tabun and
subsequently discovered sarin in 1937. These powerful agents would later be classified as
weapons of mass destruction by the United Nations Resolution 687 in 1991 (Resolution
687). Despite intensive endeavors by people around the world, some countries continue
to keep nerve agents stockpiled which pose a potential threat to military forces and
civilian populations. This research is aimed at taking considerable efforts to develop
effective medical countermeasures for those potential threats.
Nerve agents and organophosphate insecticides are very similar and general
treatment strategies are alike. The toxic actions of nerve agents are similar to one another,
although there are differences between OPs with respect to their peripheral and central
effects (Ligtenstein, 1984; Misulis et al., 1987). Nerve agents are a group of lipophilic
and volatile OPs that have high acute mammalian toxicity, and are called nerve agents
because of their effect on the CNS. The general formulae of nerve agents are very much
alike those of OP pesticides, Figure 1. Nerve agents are the most toxic and rapidly acting
of the known chemical warfare agents. The most important chemical reaction that occurs
1

with nerve agents takes place on the phosphorus atom, where the P-X bond can be easily
broken by nucleophilic reagents, such as water or hydroxyl ions. In aqueous solutions at
neutral pH, nerve agents slowly decompose. Alkali can accelerate this reaction
(Weapons, 2005). Nerve agents may take the form of gas, aerosol, or liquids. Evidence of
exposure may not be perceived by an individual until signs or symptoms occur, because
nerve agents in their purest form are colorless, odorless, and tasteless. They can be
inhaled or absorbed through the conjunctiva of the eye or through the skin. Nerve agents
in liquid form can be absorbed through the gastrointestinal tract (Grob, 1953).
The main target of nerve agents is the enzyme acetylcholinesterase, acetylcholine
acetyl hydrolase, EC 3.1.1.7, (AChE), a key component in the functioning of cholinergic
brain synapses and neuromuscular junctions (Ecobichon, 1996). Nerve agents inhibit
AChE by phosphorylating the active site of the enzyme. Phosphorylation of the active
site inhibits the ability of AChE to hydrolyze the neurotransmitter acetylcholine (ACh).
The accumulation of ACh causes over-stimulation of cholinergic synapses via muscarinic
and nicotinic acetylcholine receptors (Abdel-Rahmanl et al., 2002). The accumulation
causes hyperactivity in both the parasympathetic and sympathetic divisions of the
autonomic nervous system. This excessive stimulation leads to autonomic nervous
system effects, tremors, ataxia, convulsions, coma, and even death (Ecobichon, 2001).
Nerve agent-exposed victims usually die from respiratory failure because their respiratory
muscles become paralyzed by the action of nerve agents.
AChE is important because it is responsible for the hydrolytic degradation of the
neurotransmitter ACh, which is involved in the transmission of nerve impulses to effector
cells at neuromuscular, and cholinergic synaptic junctions. AChE consists of six active
2

sites, where each site has a central esteratic site and a peripheral anionic site (Nair and
Hunter, 2004). The esteratic site of AChE is composed of a catalytic triad of serine,
histidine and glutamic acid residues. These three acid residues perform the catalytic
functions of the enzyme. OPs phosphorylate the serine hydroxyl group in the esteratic site
of the enzyme (Marrs, 2007). The active site’s esteratic and anionic sites are involved in
the hydrolysis of ACh to acetic acid and choline. The anionic site of AChE is predicted to
be composed of multiple negative charges and attracts the positive charge present on the
nitrogen atom of ACh (Nolte et al., 1980). The nitrogen of ACh is oriented in a way that
the carbonyl group is presented to the esteratic site and an enzyme-substrate complex is
formed .The esteratic site recognizes and binds ACh. Electron shifts occur at the esteratic
site with the result in acetylation of the serine at the active site of the enzyme and choline
is released (Marrs, 2007). The acetylated enzyme complex is then hydrolyzed, freeing the
enzyme and releasing acetic acid and returning the enzyme to its original state, Figure 2
(Soreq et al., 1993).
As stated earlier, differences between OPs may exist with respect to their relative
central and peripheral effects (Ligtenstein, 1984; Misulis et al., 1987), i.e., there are
differences in the sensitivity of AChE within the nervous system in the case of soman
(Sellström et al., 1985). AChE sensitivity can be determined by an IC50, i.e., the
concentration of inhibitor that inhibits 50% of AChE activity in vitro. AChE IC50 values
reflect the intrinsic sensitivity of the AChE molecule to the inhibitor, and can be used to
predict acute toxicity levels of OPs (Mortensen et al., 1998). Many researchers have
conflicting evidence that acute toxicity as measured by LD50 correlates well with the
target enzyme sensitivity measured by IC50 (Chambers et al., 1990; Johnson and
3

Wallace, 1987; Benke and Murphy, 1975), while other researchers are concerned about
the interpretation of the IC50 value and suggested that the bimolecular rate constant (ki)
is a better tool for predicting OP toxicity. When one compares IC50 values it is important
to keep in mind that experimental conditions must be identical, or the results are
meaningless (e.g., tissue concentration, pH, temperature, assay, and incubation time).
When interpreting IC50 values it should also be kept in mind that in vitro IC50 values are
more indicative of the tissue’s buffering capacity rather than representing the sensitivity
of the AChE to inhibition by OPs (Mortensen et al., 1998). Furthermore, IC50 values do
not give a true representation of the total kinetic reaction that occurs between OPs and
AChE, although they reflect the potency of OPs (Richardson, 1999).
A phosphorylated enzyme may undergo either spontaneous reactivation or aging.
Aging occurs from the result of a non-enzymatic loss of an alkyl group from the
phosphorous atom, Figure 3. The rate of aging depends on the structure of the inhibited
enzyme produced with each OP, e.g., soman phosphorylates the active site serine of
AChE with a pinacolyl methylphosphonyl structure making the inhibition irreversible
because of the loss of the pinacolyl group, Figure 4. Aging prevents both spontaneous
and chemical induced reactivation of phosphorylated AChE stabilizing the phosphateenzyme complex (Worek et al., 2007). The time course of aging is compound dependent,
with a compound such as soman displaying very rapid aging. When comparing OPs such
as sarin and soman, rat brain AChE aging half-life differs. Harris et al. (1966) report
soman aging half-life as 0.037hr and Fleisher and Harris (1965) report sarin aging halflife as 5.8hr showing that aging is compound dependent and the rate of aging differs
among OPs. When phosphorylated AChE has aged, it can be considered irreversible, but
4

the phosphorylated enzyme can be replaced through synthesis of a new enzyme, but this
may take days. Phosphorylated AChE cannot be replaced in red blood cells and other
formed elements of the blood that lack capacity for protein synthesis (Ecobichon, 2001;
Wilson et al., 1992). When it can occur, spontaneous reactivation is an extremely slow
process (107 to 1012 fold slower than deacetylation) that involves the dephosphorylation
of the enzyme-inhibitor complex and the breaking of a covalent bond with the addition of
water (Hobbiger, 1951; Johnson et al., 2000). However, the amount of this dissociation
complex present in vitro differs among OP compounds (Burgen and Hobbiger, 1951).
The oximes that are being used in this research are newly designed pyridinium
oximes. Pyridinium oximes are formulated as different salts, i.e., iodide, chloride, lactate,
bromide; they mostly differ in their stability and solubility (Antonijevic and Stojiljkovic
2006). Pyridinium oximes are compounds containing the group RCH=NOH attached to a
pyridinium ring with a quaternary nitrogen that is capable of reactivating OP- inhibited
AChE by dephosphorylating the active site of AChE (Lorke et al., 2008). Pyridinium
oximes are oriented proximally to exert a nucleophilic attack on the enzyme inhibitor
complex. The intermediate in the reactivation is a complex between the phosphorylated
enzyme and the reactivator, in which the enzyme inhibitor-oxime complex splits off
leaving a regenerated enzyme (Antonijevic et al., 2006). The potency of oximes such as
2-PAM is attributed to the quaternary nitrogen that binds to the anionic site of AChE and
the positioning of the nucleophilic oxime moiety that supports the move of the phosphate
from the active site of AChE to the oxime (Hackley et al., 1959).
Organophosphate poisoning resulting in the inhibition of AChE traditionally has
been treated with atropine sulfate and an oxime, such as 2-PAM. Atropine antagonizes
5

the overstimulation of cholinergic receptors from accumulated ACh. Atropine is highly
effective in antagonizing ACh receptors at muscarinic receptors, but is not as effective at
nicotinic receptors, Figure 5. When used at the recommended dose levels atropine will
act as antagonist at muscarinic receptors in the CNS, preventing convulsions and
inhibition of the respiratory center (Johnson et al., 2000). The role of an oxime is to free
the inhibited enzyme from the OP and restore the enzyme function, Figure 3. The ability
of pyridinium oximes to reactivate inhibited AChE can be influenced by a number of
things: the number of quaternary pyridinium rings on the oxime (Hammond et al., 2003;
Kuca and Kassa, 2003); the shape and length of the chain that connects two quaternary
nitrogens (Kuca et al., 2003); and the position and number of oxime groups at the
pyridinium ring (Lamb et al., 1966; Kuca and Kassa, 2003). Oximes display different
characteristics such as oxime affinity and oxime reactivity which in turn can be used to
design better oximes. All of the above can determine the efficacy of an oxime, but the
therapeutic efficacy of oximes depends on many factors. It is difficult to treat OP
poisoning, and factors such as timing and the administration route for both the nerve
agent and antidote play a role.
Anticonvulsant drugs such as diazepam are also used in organophosphate
poisoning to reduce seizures and convulsions. The immediate treatment with atropine
sulfate and oxime does not always prevent nerve agent induced seizures. Prolonged
seizures as a result of organophosphate poisoning can produce irreversible brain damage
(McDonough et al., 1995; Shih et al., 2003). This can result in long term deficits in
cognitive function and behavior (Shih et al., 2007). In most cases of OP poisoning the
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central effects are mainly the results of activation of muscarinic receptors, and are
antagonized by atropine (Rang et al., 1999).
When determining reactivation constants of inhibited AChE with various nerve
agents, there are cross-species differences, e.g., human, guinea pig, rat, and rabbit that
show differences in the potency of oximes between human and animal enzymes. This
may be due to enzyme-kinetic properties of AChE, toxicokinetics of inhibitors (Benschop
and de Jong, 2001), or pharmacokinetics and dosing of antidotes (Baggot, 1994; Clement
et al., 1995; Dawson, 1994) that interfere with the extrapolation of animal data to
humans. It is known that all oximes can be toxic at a certain dose and should be given in
recommended doses when administered.
It should not be assumed that nerve agents cannot cause much damage at doses
lower than the lethal dose. People such as farm workers and factory workers who are
exposed to OPs can suffer from long term low dose exposure. These workers who are
exposed to excessive exposure to OPs can observe effects such as anxiety, agitation,
headaches, impaired memory, difficulty in concentration, and psychiatric effects (Marrs,
2007). Military personnel that might be exposed to higher doses of OPs during battle
might exhibit effects such as edema, necrosis in all cell-types, and respiratory failure that
can eventually lead to death. A variety of effects in humans and animals have been
attributed to OP exposure but it is unclear whether or not low doses can bring about longterm change in CNS function (Marrs, 2007).
It is more urgent now than it has been in the past to develop and improve the
efficacy of oxime therapeutics. Currently available oximes are not ideal reactivators
mainly due to their inability to penetrate the blood-brain barrier (BBB) and reactivate
7

AChE in the central nervous system because they are very hydrophilic. In addition it is
known that currently available oximes are not equally effective in reactivating AChE that
is inhibited by different OPs. Existing oximes can allow OP poisoning victims to survive,
by reactivating the phosphorylated AChE in the peripheral nervous system, while the
brain AChE remains considerably inhibited for an extended period of time. The design of
oximes to penetrate the BBB involves increasing the lipophilicity of the oxime in relation
to the cell membrane lipid bi-layer, i.e., endothelial cells (Tsuji, 1998). The blood-brain
barrier is formed by endothelial cells of blood capillaries. The endothelial cells form tight
junctions with adjacent cells, which subsequently form tight seals between the cells.
Tight junctions are a manifestation of the blood-brain barrier, but the features of the brain
microvascular endothelium also contribute to the limited and selective transport of
toxicants between the blood and the brain (Ge et al., 2005). The tight junction prevents
the diffusion of polar compounds through paracellular pathways, but there are other
features of the brain microvascular endothelium that contribute to the limited and
selective transport of substances between the blood and the brain. These transporters
constitute a biochemical gatekeeper that ensures active regulation and nutrient delivery of
the brain extracellular fluid, while preventing the entry of xenobiotics (Shujun et al.,
2005). The transporters belong to a group of ATP- binding cassette transporters, and Pglycoprotein is the best characterized member of this protein family (Lorke et al., 2008).
P-glycoprotein is known to be a gatekeeper in the blood-brain barrier by limiting the
entry of toxic compounds. P-glycoprotein is located directly in the membrane of
endothelial cells that forms the lipophilic barrier, making it capable of actively pumping
compounds back into the blood (Schinkel, 1999).
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It is believed that due to the virtual absence of transcytosis, lack of fenestrations
and unique properties of tight junctions in brain endothelial cells, that the BBB only
allows free diffusion of small lipophilic molecules (Lorke et al., 2008). The BBB is
equipped with a variety of translocation and uptake systems for hydrophilic compounds
such as amino acids. It is suggested that oximes that have either neutral or basic affinities
for amino acids can penetrate the BBB by one of two carrier sites in which amino acids
are transported, which are highly expressed in the BBB (Richter and Wainer,1971;
Schinkel, 1999). Much is still unknown about the BBB, but it would be important to
understand the mechanism of the BBB transport system in order to improve drugs that act
in the CNS.
The aim of this research was to determine whether a series of novel pyridinium
oximes, designed to be lipophilic enough to potentially cross the blood-brain barrier,
were effective reactivators of phosphorylated AChE in vitro. The oximes along with two
well known oximes, 2-PAM and TMB-4, were evaluated in vitro to determine the ability
of the oximes to reactivate AChE in rat brain, Figure 6. 2-PAM is a standard therapeutic
in the United States and the most well known oxime. 2-PAM reactivates phosphorylated
AChE by nucleophilic attack on the serine residue removing the phosphate moiety. In
previous studies 2-PAM has been reported to penetrate the blood-brain barrier somewhat,
although there were numerous cases of civilians dying by sarin intoxication after 2-PAM
was administered in the 1995 sarin attack in the Tokyo subway (Ohta et al., 2006). Nagao
et al. (1997) found that when using the cortex and whole blood of two victims of the
Tokyo attack as brain and blood samples, the victims’ plasma AChE activities, using the
Ellman method, were recovered by 2-PAM administration, but brain AChE activities
9

were not recovered in the victims (K. Sakurada et al., 2003). Trimedoxime (TMB-4) is a
cholinesterase reactivator that reactivates AChE better than 2-PAM, but is more toxic,
Figure 7.
Two organophosphate compounds were studied in this research to test the
efficacy of the newly developed pyridinium oximes, paraoxon and a sarin analogue that is
reflective of the nerve agent sarin. Paraoxon was used to screen the novel oximes to
select the oximes to test with the sarin analogue, Figure 8. Paraoxon is an
organophosphate, and the metabolite of the insecticide parathion. Paraoxon is used in
many in vitro studies as an AChE inhibitor because of its high inhibitory potency. The
experimental OP, phthalimidyl isopropyl methylphosphonate (PIMP), phosphorylates
AChE with the same moiety as the nerve agent sarin, but degrades quickly in aqueous
solution to prevent re-inhibition of reactivated AChE, Figure 9. PIMP will degrade in 15
minutes, thereby allowing the inhibition phase to cease. PIMP is non-volatile compared
to sarin the most volatile of the nerve agents. Sarin changes from liquid to vapor very
rapidly posing a short-lived threat. PIMP is a stable and nonvolatile analogue of sarin.
The reactivation activities of the pyridinium oximes on PIMP-exposed AChE and
structure activity relationships were examined. The reactivation potential of the oximes
was measured spectrophotometrically using a modification (Chambers et al., 1988) of the
most widely used Ellman method (Ellman et al., 1961). Three replications of each oxime
with each OP were performed. Whole rat brain was used as the source of AChE. The
lipophilicities of the oximes were also determined by octanol-water partition coefficients,
which is the simplest predictor of potential ability to cross the blood-brain barrier.
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Figure 1 The general formulae for nerve agents and organophosphates.
R= alkyl, alkoxy, or aryl group, X= leaving group
Nerve agents are never P=S

Figure 2 The normal function of acetylcholinesterase showing anionic and
esteratic sites.
The positively charged nitrogen on the acetylcholine molecule is attracted to the anionic
site on acetylcholinesterase, and hydrolysis is catalyzed at the esteratic site to form
choline and acetic acid
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Figure 3 Mechanism of OP "aging" and reactivation by 2-PAM
The nerve agent inhibits AChE by binding to the serine. 2-PAM reactivates the inhibited
AChE by nucleophillic attack of the OP compound bound to the enzyme.

Pinacolyl methylphosphonofluoridate

Isopropyl methylphosphonofluoridate

Figure 4 Structures of two organophosphate nerve agents, soman and sarin.
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Figure 5 Structure of anticholinergic, atropine

Figure 6 Structure of Pralidoxime (2-PAM)

Figure 7 Structure of 1,1’ Trimethylene bis(4-formylpyridiniumbromide)
dioxime (TMB-4)
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Figure 8 Structure of organophosphate, paraoxon.

Figure 9 Structure of sarin surrogate, phthalimidyl isopropyl methylphosphonate
(PIMP)
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CHAPTER II
MATERIALS AND METHODS
2.1

Chemicals
The sarin surrogate, phthalimidyl isopropyl methylphosphonate (PIMP), paraoxon

and all novel oximes were synthesized and generously supplied by Dr. Howard Chambers
(Department of Entomology and Plant Pathology, Mississippi State University). 2-PAM
was also provided by Dr. Howard Chambers.
2.2

Tissue Preparation for in vitro assays
Brains for in vitro analysis were obtained from Sprague-Dawley derived 250-

300g male rats. Whole brain was homogenized at a concentration of 40 mg/ml in 0.05M
Tris-HCl buffer (pH 7.4 at 37°C) using a Wheaton tissue grinder. 1.2 ml of homogenate
were placed in individual tubes and stored in a -80°C freezer; this preparation is stable for
up to a year
2.3

Percent Reactivation Determination
The determination of reactivation consisted of two phases, an inhibition phase and

a reactivation phase. In the first phase (inhibition), rat brain was incubated with paraoxon
or PIMP (designed to yield ~80% inhibition), and in the second phase (reactivation)
inhibited AChE was incubated with an oxime.

15

The first phase consists of four individual reaction tubes; tubes one and three
contain 10μl of ethanol as the OP vehicle. In tubes two and four, 10μl of paraoxon
dissolved in ethanol (0.1μM final concentration) or the sarin surrogate PIMP 10-4.75M
dissolved in ethanol (175nM final concentration) was added. The tubes were incubated
with the appropriate tissue amount of 1ml for 15 minutes.
In the second phase, 10μl of 50%DMSO:50% EtOH was added to tubes one and
two, and 10μl of a 10mM oxime dissolved in 50%DMSO:50% EtOH was added to tubes
three and four resulting in a final oxime concentration of 100μM. The discontinuous
acetylcholinesterase assay followed.
2.4

Discontinuous Acetylcholinesterase Assay
Acetylcholinesterase activity was measured spectrophotometrically using a

modification (Chambers et al., 1988) of the widely used Ellman method (Ellman et al.,
1961). Into four test tubes, 9.6 ml of buffer (0.05M Tris-HCl buffer, pH 7.4) and 0.4 ml
of homogenate from the four individual test tubes described above in the percent
reactivation determination assay were vortexed (total volume of 10ml). This was done to
obtain the proper dilution for the AChE assay. From this dilution four sets of four tubes
per set with 2 ml of the diluted homogenate were used for the discontinuous AChE assay.
The first tube of each set contained 20μl of eserine sulfate (10μM final
concentration), a specific inhibitor of AChE, and served as a blank. All tubes were
vortexed and placed in a water bath for 15 minutes at 37°C. Following the 15 minute
incubation, 20μl of acetylthiocholine (ATCh) (1mM final concentration) was added as
the substrate and the tubes were vortexed and returned to the water bath to incubate for
15 minutes. The reaction was stopped by the addition of 500 μl of a 4:1 solution of 5%
16

sodium dodecyl sulfate (SDS) and 0.024 M (5,5’-dithio-bis(nitrobenzoic acid)) (DTNB).
Each tubes contents were poured into a cuvette and the absorbance was read at 412 nm
using a Milton Roy Spectronic 1001 plus.
2.5

Percent Reactivation Calculation
The overall procedure consisted of two phases. Phase 1 was inhibition, where

AChE in brain homogenate was incubated with paraoxon or PIMP. This phase was
labeled as inhibition of A in the calculation. Phase 2 was reactivation, where inhibited
AChE was incubated with an oxime. This phase was labeled as inhibition of B in the
calculation. Inhibition and reactivation reactions were compared to appropriate controls
to calculate percent inhibition and percent reactivation. Percent reactivation was
calculated as follows: [(%IA - %IB)/%IA] x 100 (I = Inhibition). Percent inhibition of A
was determined by calculating [(T1 – T2)/T1] x 100 (T = tube). Tube one was the vehicle
control which contains EtOH (OP vehicle) + 50% DMSO: 50% EtOH (oxime vehicle).
Tube two was the oxime vehicle (organophosphate + vehicle). Percent inhibition of B
was determined by calculating [(T3 - T4)/T3] x 100 (T = tube). Tube three was the vehicle
(ethanol + oxime), and tube four organophosphate plus the oxime.
2.6

Partition Coefficients
Lipophilicity, reflecting the potential for crossing the blood-brain barrier, was

measured by determining partition coefficients. N-Octanol/water partition coefficients
were determined. Oxime was dissolved in distilled water and the solution was shaken
vigorously with an equal volume of alcohol. The alcohol phase was dried over anhydrous
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sodium sulfate, and the oxime concentration was determined by measuring the UV
absorbance.
2.7

Normality
SAS was used to determine whether the data were approximately normally

distributed. This was done to see if the data set was well-modeled by a normal
distribution.
2.8

Structure Activity Relationship
Four series of groups based on structural similarities were compared for structure-

activity relationship. Oximes differ based on the size and substituents. The structures of
the oximes are not shown for proprietary reasons.
2.9

Statistical Analysis
The results obtained from this study were statistically analyzed using Microsoft

Office Excel 2007, Sigma Plot 8.0, and SAS® System for Windows, Version 9.1. The
analysis was done to determine which oximes do not differ statistically in their
reactivation and to compare the reactivation activity for further testing in vivo. An
ANOVA test was performed on the data to determine whether the data were normally
distributed using SAS®. At the level p<0.05 the General Linear Model (GLM) procedure
was used to conclude a significant difference between 2-PAM and the novel oximes, and
within ANOVA a mean separation of the oximes was done. Oximes were grouped by
similarity in structure and relative potency in comparison to 2-PAM was determined
using Microsoft Excel 2007.
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CHAPTER III
RESULTS
Twenty-eight novel oximes were synthesized and tested for their abilities to
reactivate rat brain AChE following its inhibition by PIMP in vitro. All the oximes tested
demonstrated some ability to reactivate inhibited AChE. Reactivation varied among the
novel oximes 24-78% (Table 1) and the novel oximes were not as effective as 2-PAM or
TMB-4, which reactivated 91% and 97%, respectively. Compared to 2-PAM, the novel
oximes displayed efficacy of 37% to 86%. The lipophilicity for all the oximes was
greater than 2-PAM or TMB-4 by 3-to 374-fold.
Twenty-eight oximes were tested for their efficacy of reactivating inhibited
AChE, and of those 28 oximes 12 were tested with paraoxon. When using SAS to
compare whether or not the two inhibitors were significantly different, it was determined
that the two inhibitors, PIMP and paraoxon, were not significantly different at the 0.05
level of significance (Pr > F = 0.0716). To test whether the effects of the two inhibitors
were significantly different one-way ANOVA was used. The novel oximes were more
effective in reactivating AChE inhibited by paraoxon, but there was not a substantial
difference between the two (Figure 10). When looking at the comparison chart of the
inhibitors, oximes 2, 3, 6, 11, and 15 seemed to be substantially different. For this reason
a student t-test was run on the oximes. When running the student t-test 5 of the 12
comparisons were significantly different, which were oximes 2, 3, 6, 11, and 12 (table 2).
19

Rat brain AChE showed low to moderate reactivation by the oximes when
inhibited by PIMP (Table 1). In table 1, values are expressed as mean ± standard
deviation (SD) where n=3. Significant differences were determined using SAS, where
normality was also determined. To test whether the novel oximes have the same effect as
2-PAM, t-tests were run to determine whether or not the oximes were significantly
different from 2-PAM. It was determined to reject the null hypothesis that they are
similar. 2-PAM reactivated inhibited AChE better than all the novel oximes. When
running distribution analysis using SAS to test for normality the Shapiro-Wilk,
Kolmogorov-Smirnov, Cramer-von Mises, and Anderson-Darling tests were run in which
the results were normally distributed. To better visualize this, a QQ plot was run to check
for normality using the average of the means (figure 11).
To better visualize the reactivation potential of the novel oximes in comparison to
2-PAM, figures 12-15 compared the relative potency of all oximes to 2-PAM. Oximes
were grouped by similarity in structure to evaluate the reactivation potential. 2-PAM is
given the number of 1 (Oxime/2-PAM=Relative Potency). In figure 12, 2 of 5 oximes
showed above average reactivation potency and varied from 0.41 to 0.86. Group 2 (figure
13) had the most oximes with relative potency in the average range from 0.26-0.79.
Group 2 had 6 out of 14 oximes showing average reactivation in comparison to 2-PAM.
Group 4 (figure 14) had only one oxime out of 5 showing above average reactivation, and
group 5 (figure 15) only had two oximes showing an average reactivation in comparison
to 2-PAM. Although 2-PAM reactivated AChE better than the novel oximes, it showed
the lowest lipophilicity. Lipophilicity ranged from 0.009 to 2.244 (Table 1).
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Table 1

Characterization of novel oximes in vitro

Oxime

% Rat Brain
Relative
Lipophilicity**
Relative
Reactivation*
Reactivation
Lipophilicity
2-PAM
91±5
1.00
0.006
1.0
TMB-4
97±4
1.10
<0.001
0.2
Oxime 1
37±6
0.41
0.029
4.8
Oxime 2
37±5
0.41
0.020
3.3
Oxime 3
39±4
0.44
0.009
1.5
Oxime 4
65±5
0.71
0.138
23
Oxime 5
78±3
0.86
0.117
19.5
Oxime 6
41±1
0.45
0.084
14
Oxime 7
49±4
0.54
0.072
12
Oxime 8
53±4
0.58
0.017
2.8
Oxime 9
54±10
0.60
0.128
21.3
Oxime 10
47±3
0.52
0.051
8.5
Oxime 11
46±6
0.51
0.031
5.2
Oxime 12
34±2
0.37
0.018
3
Oxime 13
34±2
0.37
0.034
5.7
Oxime 14
65±8
0.71
0.184
30.7
Oxime 15
24±4
0.26
0.680
113.3
Oxime 16
43±1
0.47
0.045
7.5
Oxime 17
72±8
0.79
0.174
29
Oxime 18
72±5
0.79
0.172
28.7
Oxime 19
56±6
0.62
0.352
58.7
Oxime 20
30±6
0.33
0.042
7
Oxime 21
39±1
0.42
0.146
24.3
Oxime 22
38±6
0.42
0.031
5.2
Oxime 23
48±3
0.52
0.056
9.3
0.318
53
Oxime 24
71±7
0.78
Oxime 25
42±1
0.46
0.084
14
Oxime 26
48±1
0.51
0.045
7.5
Oxime 27
28±2
0.31
0.538
89.7
Oxime 28
25±4
0.27
2.244
374
* 15-min incubation with PIMP following 30-min incubation with 100μM oxime, n=3
replications, mean ± SD
** n- Octanol/water partition coefficient Relative reactivation and lipophilicity as
compared to 2-PAM
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Figure 10 Mean comparison of PIMP and Paraoxon
Values are expressed as mean ± SD (n=3). Significant differences were determined using
SAS where it was determined that the two inhibitors are not significantly different at the
0.05 level of significance.
Table 2

Student t-test of Paraoxon/PIMP comparison

Paraoxon Rep 1 Rep 2 Rep 3 PIMP Rep 1 Rep 2 Rep 3 P-Value
2 69.80 68.85 46.91
2 32.64 36.28
42.47 0.036674
3 73.18 75.96 95.38
3 41.33 42.79
35.83 0.004711
4 50.18 59.26 42.07
4 68.82 59.87
66.63 0.060984
6 46.05 53.39 57.38
6 39.95 42.20
40.59 0.028406
7 52.91 58.58 76.54
7 44.19 52.34
50.44 0.143505
9 55.16 57.69 62.29
9 52.01 64.92
44.68 0.533711
11 70.37
82.6 89.59
11 51.37 46.56
39.91 0.010409
15 42.69 43.57 57.01
15 27.55 26.06
19.56 0.020449
16 42.31 36.42 48.25
16 43.03 44.17
41.53 0.875702
17 82.00 92.46 104.20
17 72.69 80.48
63.98 0.062215
20 30.92 38.92 33.78
20 30.82 36.18
24.23 0.378422
21 47.64 63.14 51.45
21 39.86 38.24
38.28 0.079971
Comparison of three replications of individual oxime with paraoxon and PIMP
* Less than 0.05 for the p-value, there is a significant difference in the reactivation
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Table 3

Reactivation activities of novel oximes in vitro when using paraoxon
Oxime
2
3
4
6
7
9
11
15
16
17
20
21

Rep 1
Rep 2
Rep 3
AVG
STD DEV
69.80
68.85
46.91
61.85
12.95
73.18
75.96
95.38
81.50
12.09
50.18
59.26
42.07
50.50
8.59
46.05
53.39
57.38
52.27
5.74
52.91
58.58
76.54
62.67
12.33
55.16
57.69
62.29
58.38
3.61
70.37
82.60
89.59
80.85
9.72
42.69
43.57
57.01
47.75
8.02
42.31
36.42
48.25
42.32
5.91
82.00
92.46
104.2
92.88
11.10
30.92
38.92
33.78
34.54
4.05
47.64
63.14
51.45
54.07
8.07

15-min incubation with paraoxon following 30-min incubation with 100μM oxime
Rep= Replications. 3 replications were run on each oxime to test for efficacy.
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Figure 11 Normal probability test for normality testing
QQ plot showing that the assumption that the data are approximately normally distributed
is acceptable.
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Figure 12 Chart showing relative potency of 5 oximes compared to 2PAMranging from 0.41-0.86
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Figure 13 Chart showing relative potency of 14 oximes compared to 2-PAM
ranging from 0.37-0.60.
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Figure 14 Chart showing relative potency of 5 oximes compared to 2-PAM
ranging from 0.33-0.78.
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CHAPTER IV
DISCUSSION
The ability to quickly reactivate organophosphate inhibited AChE is extremely
important in the event of nerve agent exposure. Current therapies for organophosphate
poisoning (atropine and 2-PAM) are effective in reactivation of peripheral AChE, usually
preventing death. However, 2-PAM and other existing oximes have very limited or no
ability to cross the blood- brain barrier (BBB) and reactivate AChE. In this research, 28
novel oximes were designed and synthesized to be more lipophilic and the ability of these
novel oximes to reactivate AChE were tested in vitro. While reactivation potencies were
not as great as those of 2-PAM or TMB-4, there was appreciable reactivation showing
that these oxime chemistries do have potential, and the lipophilicities have been greatly
enhanced.
The function of the BBB is to protect the CNS from toxic molecules; this includes
toxins ingested in food, inhaled, or absorbed through the skin. However the BBB also
serves as a barrier to potentially beneficial drugs that will aid in the reactivation of
inhibited AChE due to organophosphate poisoning (Haberman, 2009). The aim of this
research was to determine whether a series of novel pyridinium oximes
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synthesized to increase lipophilicity and thereby increase their likelihood of crossing the
BBB, could effectively reactivate phosphorylated AChE in vitro. The results of this
research demonstrate that it is possible to design an oxime that is potentially lipophilic
enough (all novel oximes exceed the lipophilicity of 2-PAM) to penetrate the BBB and be
effective in reactivating inhibited AChE in the CNS.
The role of an oxime is to remove the organophosphate moiety from the inhibited
enzyme and restore the enzyme function. All oximes tested did not reach target
reactivation efficacy(~50%). The mean reactivation rate of the oximes were significantly
different when comparing the oximes to 2-PAM. This suggests that there are differences
among the oximes in their ability to reactivate inhibited AChE. The ability of these
oximes to reactivate AChE inhibited by phthalimidyl isopropyl methylphosphonate
(PIMP) can depend on many things such as chemical structure of the inhibitor and
reactivator, time of inhibition and reactivation, conditions (i.e., temperature, pH), and
contamination of enzyme source (Kuca et al., 2007). For example, obidoxime is thought
to be somewhat better that 2-PAM in treating victims with nerve agent poisoning, but
obidoxime (a 4-position oxime) forms a stable phosphoryl oxime that inhibits reactivated
AChE which may limit its use in the treatment of nerve agent poisoning. This explains
the importance of why the chemical structure of the inhibitor and reactivator are
important in oxime development. In tissue homogenates there are enzymes that are
present which can interfere with the assay by reacting with substrates or products of assay
reactions (Scheer et al., 2004). In this research the oxime/inhibitor is assayed directly in
brain tissue homogenate under conditions in which the effect of possible contamination
are minimal, and allows for more accurate results of the efficacy of the oximes.
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The activities of the twenty-eight novel oximes are shown as relative activities
compared to 2-PAM. 2-PAM is the current standard treatment for organophosphate
poisoning in the United States. Current reactivators include different types of oximes
with a similar basic structure differing by number of pyridinium rings and by the position
of the oxime group in the pyridinium ring (Kuca et al., 2007). Structure-activity
relationship is what helps to improve and synthesize new oximes. These twenty-eight
novel oximes vary in their ability to reactivate inhibited AChE as well as in their
structure. No single oxime is the same. Kuca et al. (2007) stated that the differences in
the oxime efficacy toward nerve agents can be caused by oxime concentration in the
target organs and various aging rate at which inhibited AChE is converted to a form that
can no longer be reactivated by oximes. The actual oxime concentration that is present in
the brain tissue homogenate may differ. Oxime concentration in peripheral target sites is
practically the same as its concentration in the blood (Kassa, 2002; Bajgar, 2004; Worek
et al., 2005). In in vitro analysis the exact determination of the reactivating potency of
oximes requires the consideration of different reactions between AChE, OP, and oxime.
Post-inhibitory reactions of AChE, aging, and spontaneous reactivation by oximes may
affect the reactivation when testing in vitro. The therapeutic efficacy of a reactivator is
dependent on its concentration in the brain tissue homogenate during incubation and on
the reactivatability of inhibited AChE (Kuca et al., 2007).
A major factor in oxime penetration of the BBB is chemical structure. The polar
ionic character of many oximes causes restriction by the blood-brain and the blood
cerebrospinal fluid barriers. For this reason, the lipophilicity of an oxime is the simplest
predictor of its potential to cross the BBB. This study’s ultimate goal was to develop and
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synthesize a phenoxyalkyl pyridinium oxime that was sufficiently lipophilic to penetrate
the BBB, yet still be effective in reactivating AChE. Some oximes had considerably low
reactivation rates, but possessed average lipophilicity. For example, oxime 28 had an
average reactivation rate of 25% but its lipophilicity was very high at 2.244. Oxime 5, on
the other hand was found to be the most effective reactivator but its lipophilicity was low
at 0.117. It seems there is a median where limited reactivation and lipophilic potential can
be effectively achieved. It was observed that lower reactivation rates seem to correlate
with higher lipophilicity with some variability, which makes these oximes beneficial for
testing in vivo.
When testing relative potency to 2-PAM, oximes 6-12 showed the least amount of
range in reactivation. The reactivation ranged from 34-54% and lipophilicity from 0.018
and 0.128. Although this group of oximes did not vary in range of reactivation much,
most of the oximes were below 50% and lipophilicity low. This suggest that due to the
design of these particular oximes, potential for crossing the BBB and successfully
reactivating inhibited AChE in vivo is not likely.
These differences can be due to many factors; as stated earlier an oxime’s ability
to reactivate AChE as well as penetrate the BBB has a lot to do with its chemical
structure. It has been noted by many researchers that reactivation potency depends on
structural factors, such as the number of pyridinium rings, the position of functional
oxime groups, and the length of the bridge between two pyridinium rings (Jun et al.,
2006; Ohta et al., 2006). Ohta et al. (2006) noted that when testing 40 hydrophobic PAM
type oxime antidotes that were inhibited by a sarin analogue, 2-PAM showed the best
recovery activity, but the activities of the PAM analogues were reduced by side chain
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elongation. Berend et al. (2008) also investigated four new pyridinium derivatives with
similar basic structure, but differed in length of the linker between two pyridinium rings
and in the position of the oxime group in the pyridinium to determine their reactivating
potency in human erythrocyte AChE, one of the four oximes showed a better reactivating
potency than TMB-4. This was believed to be due to the position of the oxime group and
the length between two pyridinium rings in the oxime structure (Berend et al., 2008).
Although the novel oximes that were studied differ in their position of the oxime group
on the pyridine ring, their reactivity is comparable because of the similarity in basic
structure (Kassa, 2002).
The use of nerve agents is strictly controlled, and can be dangerous to
inexperienced laboratory workers. PIMP is a considerably safer and non-volatile
analogue of sarin that is conveniently prepared for testing of the novel oximes, and is
substantially less hazardous to laboratory personnel. PIMP proved to be a good test agent
that worked just as well in inhibiting AChE as paraoxon, and is considerably more
relevant to nerve agent therapy. The phthalimidyl derivative degrades quickly in aqueous
solution; this is particularly useful in in vitro assays of reactivation efficacy to prevent reinhibition of reactivated AChE and therefore provide more accurate results. PIMP leaves
AChE phosphorylated by the same chemical moiety as sarin and therefore provides a
particularly useful chemical surrogate. In comparison to recent studies done by Ohta et
al. (2006), who synthesized a non-toxic and stable sarin analogue (isopropyl pnitrophenyl methylphosphate, INMP) to evaluate nerve agent antidotes; PIMP can be
easily handled, it enabled rapid assay of reactivation activities of a large number of
oximes, and provided rapid screening and evaluation of oximes.
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Paraoxon and nerve agents are highly toxic OPs with high inhibition potency
against AChE (Jun et al., 2008). Paraoxon proved to be a good inhibitor to test the
potency of the novel oximes, and when comparing PIMP to paraoxon there is no
significant difference between the two. In a recent study testing the potency of several
oximes using paraoxon as the inhibitor for rat brain AChE, only obidoxime and
trimedoxime reached sufficient reactivation efficacy, using the modified Ellman method
for AChE activity analysis. Petroianu et al. (2006) have shown that, in rats, paraoxon
induced mortality can be reduced by administration of oximes, but the protection
conferred is insufficient considering that 30-90% of the animals died despite oxime
treatment. These results lead to the conclusion that, whether inhibited by
organophosphorus pesticides or nerve agents, there is no one oxime that is a good
reactivator of poisoning from all types of OPs, and furthermore able to counteract CNS
effects of organophosphates.
In vitro analysis is vital in the development of new AChE reactivators since the
results can determine the most potent AChE reactivators for in vivo testing. In vitro
testing can be used to determine the oxime’s affinity toward intact and inhibited AChE
(Kuca, 2005). Because in vitro studies always lack the complexity of in vivo systems,
there is always the concern that in vitro data may not accurately reflect the oxime’s
potential in vivo, but many studies have proved this may not be the case. In vitro testing
however does allow for the early exclusion of candidate oximes that reactivate AChE
poorly, thereby reducing the amount of animal testing required. This is beneficial for both
ethical and financial reasons. In vitro testing also allows the interaction of an oxime with
the pharmacological target and in this particular research it would be the interaction with
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AChE. Several studies have demonstrated that there is a correlation between in vitro and
in vivo data, and the effectiveness of an oxime primarily depends on its ability to
reactivate nerve agent inhibited AChE (Oldiges et al., 1970; Schoene et al., 1973). If the
in vitro oxime reactivation of PIMP inhibited rat brain AChE reactivates in a similar way
to that of human AChE, it is likely that the results of in vivo animal study will reliably
extrapolate to humans (Luo et al., 2007).
In summary, the importance of reactivating OP-inhibited brain AChE should not
be underestimated. Of all currently available oximes it is important to note that the
pyridinium oximes appear to be the most effective at demonstrating AChE reactivation
potential. Twenty-eight novel pyridinium oximes have been synthesized and tested for
the reactivation potential. The data indicate that these oximes can reactivate inhibited
AChE, and potentially cross the BBB. This furthermore proves that an oxime can be
developed to show better BBB penetration than currently available oximes. It also worthy
to note that these oximes in conjunction with 2-PAM can possibly be beneficial for
survival of and effective recovery from nerve agent intoxication.
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APPENDIX A
DUNNETT TEST
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When comparing the oximes to 2-PAM, 28 different hypothesis test were run. For
each test there is a 5% chance of making a type I error to reject the null hypothesis when
you are not supposed to but, overall there is a much larger chance of making at least one
Type I error over all 28 tests. This probability is 1-(1-.05)^28= .7622. Thus having a 76%
chance of making at least one type I error when conducting 28 tests. To make this
probability smaller, the Dunnett test is used that guarantees that the probability that you
are making at least one Type I error is .05, instead .7365 if no correction is used. The
Dunnett’s test compared the group means (n=3) to a reference group (2-PAM) where the
difference between means where determined at a 95% confidence limits for LSMean (i) –
LSMean (j) where (i) is the oxime and (j) is the three replications ran for each oxime.
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